Relay Therapeutics Hits 52-Week High on Earnings Beat

Biotech firm's stock surges after reporting better-than-expected Q4 results

Feb. 27, 2026 at 4:19pm

Got story updates? Submit your updates here. ›

Relay Therapeutics, Inc. (NASDAQ:RLAY) saw its stock price hit a new 52-week high of $10.99 on Friday after the company reported fourth-quarter earnings that exceeded analyst expectations. The biotech firm, which is focused on developing precision therapies for oncology, posted revenue of $7 million for the quarter, compared to the consensus estimate of $4.34 million.

Why it matters

Relay Therapeutics' strong earnings performance and resulting stock price surge highlight the company's progress in advancing its drug discovery pipeline and validating its computational-based approach to identifying promising drug candidates. As a clinical-stage biotech, Relay's ability to deliver positive financial results is a key indicator of its potential to bring innovative cancer treatments to market.

The details

Relay Therapeutics reported a Q4 loss of $0.32 per share, beating the consensus estimate of a $0.38 per share loss. The company's revenue for the quarter was $7 million, well above the $4.34 million that analysts had projected. Relay's stock price jumped nearly 20% on the news, reaching a new 52-week high. The company's shares have now more than doubled in value since the start of the year.

  • Relay Therapeutics reported its Q4 2025 earnings on February 27, 2026.

The players

Relay Therapeutics

A clinical-stage biotechnology company focused on developing precision therapies for oncology, leveraging computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates.

Sanjiv Patel

Chief Executive Officer of Relay Therapeutics.

Donald A. Bergstrom

Insider at Relay Therapeutics who sold 18,895 shares of the company's stock in January 2026.

Got photos? Submit your photos here. ›

The takeaway

Relay Therapeutics' ability to deliver positive financial results as a clinical-stage biotech is a promising sign for the company's potential to bring innovative cancer treatments to market through its unique computational drug discovery platform.